BusinessSummit to Present Additional Data From Phase 2 CoDIFy Trial Showing Ridinilazole’s Statistical Superiority Over Vancomycin in Sustained Clinical Response was Driven by Marked Reduction in Recurrence of C. difficile InfectionBy Nasdaq OMXMar 29, 2016, 1:25 PM UTC
BusinessAssembly Biosciences to Webcast Upcoming Investor ConferencesBy Nasdaq OMXFeb 19, 2016, 12:30 PM UTC
BusinessAssembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technology Achieves Targeted Delivery to the Lower GI TractBy Nasdaq OMXJan 27, 2016, 12:30 PM UTC
BusinessClinical Study Shows Assembly Biosciences' Oral Gemicel™ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other ApplicationsBy Nasdaq OMXDec 9, 2015, 12:00 PM UTC
